EUVIMEDEUVIMED entdecken
Vergleichsstudie

Transarterial Chemoembolization (TACE) Combined with Lenvatinib versus TACE Alone in Intermediate-Stage Hepatocellular Carcinoma Patients Beyond Up-To-Seven Criteria: A Retrospective, Propensity Score-Matched Analysis

Churen Zhou, Boyang Chang, Zhanwang Xiang, Zhengran Li, Chun Wu, Mingjun Bai, Zaibo Jiang, Mingsheng Huang, Junwei Chen

Academic Radiology · 2024-11 · 31 (11) · 4456-4465

DOI: 10.1016/j.acra.2024.04.045 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Academic Radiology, 2024-11. Verfasst von Churen Zhou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interventional Radiology, the Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510630, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Chemoembolization, Therapeutic, Quinolines. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RATIONALE AND OBJECTIVES: To compare the treatment efficacy and safety of transarterial chemoembolization (TACE) combined with lenvatinib versus TACE alone in patients with intermediate-stage hepatocellular carcinoma (HCC) beyond up-to-seven criteria. MATERIALS AND METHODS: A total of 107 newly diagnosed HCC patients with Barcelona Clinic Liver Cancer stage B HCC beyond up-to-seven criteria were included in this retrospective cohort study. These patients were divided into two groups: TACE-Lenv group and TACE alone group. Propensity score matching was used to account for potential confounding factors. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), downstaging rate, liver function, and adverse events (AEs) were recorded and evaluated. RESULTS: Both the median OS and median PFS were significantly longer in the TACE-Lenv group compared to the TACE alone group (median OS: 28.0 vs 12.0 months, P = 0.017; median PFS [mRECIST]: 8.2 vs 3.7 months, P = 0.018; median PFS [RECIST v1.1]: 8.9 vs 3.7 months, P = 0.003). Furthermore, the ORR and DCR were also significantly higher in TACE-Lenv group (ORR: 94% [30/32] vs 47% [15/32], P < 0.001; DCR: 97% [31/32] vs 62% [20/32], P < 0.001). There were no significant differences in terms of liver function and grade 3 or 4 AEs rate between two groups. CONCLUSION: The combination of TACE and lenvatinib provides clinical benefits for patients with intermediate HCC beyond the up-to-seven criteria, has an acceptable safety profile, shows a trend towards improving liver function, and does not increase the occurrence of grade 3-4 AEs. KEY POINTS: The efficacy of transarterial chemoembolization in intermediate-stage hepatocellular carcinoma patients is partially unsatisfactory. Addition of lenvatinib to transarterial chemoembolization improves OS, PFS, ORR, and DCR for patients with intermediate-stage hepatocellular carcinoma beyond the up-to-seven criteria. This combination therapy is a superior treatment option for intermediate-stage hepatocellular carcinoma patients with high tumor burden.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsChemoembolization, TherapeuticQuinolinesPropensity ScorePhenylurea CompoundsHumansMaleFemaleRetrospective StudiesMiddle AgedAgedTreatment OutcomeAntineoplastic AgentsCombined Modality TherapyNeoplasm StagingAdult

Stichwörter der Autor:innen

Hepatocellular carcinoma (HCC)Intermediate stage (BCLC-B)Transarterial chemoembolization (TACE)Tyrosine kinase inhibitor (TKI)Up-to-seven criteria

Substanzen

lenvatinibQuinolinesPhenylurea CompoundsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Interventional Radiology, the Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510630, China.
  • Department of Interventional Radiology, the Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510630, China. Electronic address: chenjw53@mail.sysu.edu.cn.

Zitieren

APA

Zhou, C., Chang, B., Xiang, Z., Li, Z., Wu, C., Bai, M., Jiang, Z., Huang, M., & Chen, J. (2024). Transarterial Chemoembolization (TACE) Combined with Lenvatinib versus TACE Alone in Intermediate-Stage Hepatocellular Carcinoma Patients Beyond Up-To-Seven Criteria: A Retrospective, Propensity Score-Matched Analysis. Academic Radiology, 31(11), 4456-4465. https://doi.org/10.1016/j.acra.2024.04.045

Vancouver

Zhou C, Chang B, Xiang Z, Li Z, Wu C, Bai M, et al. Transarterial Chemoembolization (TACE) Combined with Lenvatinib versus TACE Alone in Intermediate-Stage Hepatocellular Carcinoma Patients Beyond Up-To-Seven Criteria: A Retrospective, Propensity Score-Matched Analysis. Academic Radiology. 2024;31(11):4456-4465. doi:10.1016/j.acra.2024.04.045

BibTeX
@article{Zhou2024,
  author = {Zhou, Churen and Chang, Boyang and Xiang, Zhanwang and Li, Zhengran and Wu, Chun and Bai, Mingjun and Jiang, Zaibo and Huang, Mingsheng and Chen, Junwei},
  title = {Transarterial Chemoembolization (TACE) Combined with Lenvatinib versus TACE Alone in Intermediate-Stage Hepatocellular Carcinoma Patients Beyond Up-To-Seven Criteria: A Retrospective, Propensity Score-Matched Analysis},
  journal = {Academic Radiology},
  year = {2024},
  volume = {31},
  number = {11},
  pages = {4456--4465},
  doi = {10.1016/j.acra.2024.04.045}
}
Kostenlos starten →